DGIdb - PYRIDOSTIGMINE Drug Record

PYRIDOSTIGMINE chembl:CHEMBL1115 Approved

Alternate Names:

REGONOL
MESTINON
PYRIDOSTIGMINE
MESTINON®
REGONOL®
BROMURO DE PIRIDOSTIGMINA
PYRIDOSTIGMIN BROMID
BROMURE DE PYRIDOSTIGMINE
PYRIDOSTIGMINI BROMIDUM
pubchem.compound:4991
chemidplus:155-97-5
rxcui:9000
chembl:CHEMBL1115
drugbank:00545

Drug Info:

Drug Class	antimyasthenics
Year of Approval	1955
Drug Class	small molecule
Drug Indications	Antimyasthenics
FDA Approval	1955

(1 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Ricordel et al., 2000, [Chemical weapons: antidotes. View about the real means, perspectives]., Ann Pharm Fr
Servatius et al., 2000, Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats., Physiol. Behav.
Drake-Baumann et al., 1999, Effects of exposure to low-dose pyridostigmine on neuromuscular junctions in vitro., Muscle Nerve
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Prasad et al., 2000, Interactions of bovine brain tubulin with pyridostigmine bromide and N,N'-diethyl-m-toluamide., Neurochem. Res.
Sinton et al., 2000, Stressful manipulations that elevate corticosterone reduce blood-brain barrier permeability to pyridostigmine in the Rat., Toxicol. Appl. Pharmacol.

PYRIDOSTIGMINE ACHE

Interaction Score: 2.26

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10669805 10869589 10366222 11752352 10685600 10814558

Sources:
TdgClinicalTrial TEND TTD
PYRIDOSTIGMINE CBX1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PYRIDOSTIGMINE CYP2C9

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PYRIDOSTIGMINE CYP1A2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PYRIDOSTIGMINE CYP2D6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PYRIDOSTIGMINE CYP3A4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: PYRIDOSTIGMINE
- Version: 01-August-2011
Alternate Names:

PYRIDOSTIGMINE Primary Drug Name

Drug Info:

Year of Approval 1955

Drug Class antimyasthenics

Publications:
TdgClinicalTrial: PYRIDOSTIGMINE
- Version: January-2014
Alternate Names:

Drug Info:

FDA Approval 1955

Drug Indications Antimyasthenics

Drug Class small molecule

Publications:
DTC: PYRIDOSTIGMINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1115 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
TTD: Pyridostigmine
- Version: 2020.06.01
Alternate Names:

D0O2WB TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1115
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

antagonist (inhibitory)
inhibitor (inhibitory)

Trial Name	-
Novel drug target	Established target

PYRIDOSTIGMINE Drug Record

PYRIDOSTIGMINE chembl:CHEMBL1115 Approved

Alternate Names:

Drug Info:

Publications:

PYRIDOSTIGMINE ACHE

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 10669805 10869589 10366222 11752352 10685600 10814558

Sources: TdgClinicalTrial TEND TTD

PYRIDOSTIGMINE CBX1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

PYRIDOSTIGMINE CYP2C9

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

PYRIDOSTIGMINE CYP1A2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

PYRIDOSTIGMINE CYP2D6

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

PYRIDOSTIGMINE CYP3A4

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: PYRIDOSTIGMINE

Alternate Names: PYRIDOSTIGMINE Primary Drug Name

Drug Info: Year of Approval 1955 Drug Class antimyasthenics

Publications:

TdgClinicalTrial: PYRIDOSTIGMINE

Alternate Names:

Drug Info: FDA Approval 1955 Drug Indications Antimyasthenics Drug Class small molecule

Publications:

DTC: PYRIDOSTIGMINE

Alternate Names: CHEMBL1115 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

TTD: Pyridostigmine

Alternate Names: D0O2WB TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1115

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
10669805 10869589 10366222 11752352 10685600 10814558

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

PYRIDOSTIGMINE Primary Drug Name

Drug Info:

Year of Approval 1955

Drug Class antimyasthenics

Drug Info:

FDA Approval 1955

Drug Indications Antimyasthenics

Drug Class small molecule

Alternate Names:

CHEMBL1115 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

D0O2WB TTD Drug ID